Reference information for the recordAccession Number: | 00002256-201909000-00019.
|
Author: | Courlet, Perrine 1; Guidi, Monia 1,2; Glatard, Anais 1,3; Alves Saldanha, Susana 1; Cavassini, Matthias 4; Buclin, Thierry 1; Marzolini, Catia 5; Eap, Chin B. 2,3; Decosterd, Laurent A. 1; Csajka, Chantal *,1,2; the Swiss HIV Cohort Study
|
Institution: | (1) Service of Clinical Pharmacology Lausanne University Hospital and University of Lausanne Lausanne Switzerland (2) School of Pharmaceutical Sciences, University of Geneva University of Lausanne Geneva Switzerland (3) Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Hospital of Cery Lausanne University Hospital and University of Lausanne Prilly Switzerland (4) Service of Infectious Diseases Lausanne University Hospital and University of Lausanne Lausanne Switzerland (5) Departments of Medicine and Clinical Research University Hospital of Basel and University of Basel Switzerland
|
Title: | |
Source: | British Journal of Clinical Pharmacology. 85(9):2022-2032, September 2019.
|
Author Keywords: | pharmacokinetics; drug interactions < pharmacokinetics; HIV/AIDS < infectious diseases; NONMEM < pharmacodynamics.
|
References: | 1. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158(5):725-730.
2. Eller LS, Bunch EH, Wantland DJ, et al. Prevalence, correlates, and self-management of HIV-related depressive symptoms. AIDS Care. 2010;22(9):1159-1170.
3. Bhatia MS, Munjal S. Prevalence of depression in people living with HIV/AIDS undergoing ART and factors associated with it. J Clin Diagn Res. 2014;8(10):WC01-WC04.
4. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136-S139.
5. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573-580.
6. Caballero J, Nahata MC. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann Pharmacother. 2005;39(1):141-145.
7. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157-160.
8. Drewes P, Thijssen I, Mengel H. A single-dose, cross-over pharmacokinetic study comparing racemic citalopram (40 mg) with the S-enantiomer of citalopram (escitalopram, 20 mg) in healthy male volunteers. Annual Meeting of the New clinical Data Evaluation Unit; May 29-June 1; Phoenix, USA.2001.
9. Lundbeck . Information de base, Cipralex 2006. Available from: http://www.cipralex.ch/pdf/basis...- opens in a new window. Accessed December 11, 2018.
10. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality. 1997;9(7):686-692.
11. Swissmedic . Information Sur le medicament. [Available from: http://www.swissmedicinfo.ch/- opens in a new window. Accessed December 6, 2017.
12. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29(8):1102-1109.
13. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62.
14. Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol. 2007;10(6):777-785.
15. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161(5):826-835.
16. Hasnain M, Howland RH, Vieweg WV. Escitalopram and QTc prolongation. J Psychiatry Neurosci. 2013;38(4):E11.
17. Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013;76(1):48-57.
18. Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol. 2006;61(2):177-190.
19. van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. Br J Clin Pharmacol. 2012;73(3):402-410.
20. Food and Drug Administration . FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012.
21. CredibleMeds . University of Arizona centres for Education & Research on therapeutics (AZCERT). [Available from: https://www.crediblemeds.org/- opens in a new window. Accessed December 7, 2017.
22. Citalopram and escitalopram: QT interval prolongation. New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Available from: https://www.gov.uk/drug-safety-u...- opens in a new window, (2011). Accessed February 16, 2018.
23. Choong E, Quteineh L, Cardinaux JR, et al. Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. JAMA Psychiat. 2013;70(10):1011-1019.
24. Ansermot N, Brawand-Amey M. Eap CB. Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomedic Life Sci. 2012;885-886:117-130.
25. Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res. 2008;58(5-6):344-347.
26. Tanum L, Strand LP, Refsum H. Serum concentrations of citalopram--dose-dependent variation in R- and S-enantiomer ratios. Pharmacopsychiatry. 2010;43(5):190-193.
27. Lindbom L, Pihlgren P, Jonsson EN. PsN-toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-257.
28. Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1):72-79.
29. Akil A, Bies RR, Pollock BG, et al. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016;43(1):99-109.
30. Jin Y, Pollock BG, Frank E, et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol. 2010;50(1):62-72.
31. Jin Y, Pollock BG, Frank E, et al. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. J Clin Pharmacol. 2009;49(2):176-184.
32. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-290.
33. Shin K, Kim E, Kim S, et al. Population pharmacokinetics and pharmacodynamics of escitalopram in healthy volunteers. Annual Meeting of the Population Approach Group in Europe; Venice2012.
34. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434-438.
35. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205-216.
36. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003;25(4):1200-1210.
37. Siccardi M, Marzolini C, Seden K, et al. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet. 2013;52(7):583-592.
38. Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90-97.
39. Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290.
40. Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos. 2013;41(7):1414-1424.
41. Service de pharmacologie et toxicologie cliniques, Hopitaux Universitaires de Geneve. Interactions medicamenteuses, cytochromes P450 et P-glycoproteine (Pgp). Available from: https://www.hug-ge.ch/sites/inte...- opens in a new window. Accessed August 7, 2017.
42. Food and Drug Administration . Drug development and drug interactions: table of substrates, inhibitors and inducers. Available from: https://www.fda.gov/drugs/develo...- opens in a new window. Accessed December 20, 2017.
43. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503-512.
44. Harding SD, Sharman JL, Faccenda E, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res. 2018;46(D1):D1091-D1106.
45. Alexander SPH, Fabbro D, Kelly E, et al. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol. 2017;174(Suppl 1):S272-S359.
46. de Mendonca Lima CA, Baumann P, Brawand-Amey M, et al. Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):952-956.
47. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003;25(2):183-191.
48. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004;44(12):1352-1359.
49. Sogaard B, Mengel H, Rao N, Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005;45(12):1400-1406.
50. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83(2):322-327.
51. Chang M, Tybring G, Dahl ML, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014;53(9):801-811.
52. Ji Y, Schaid DJ, Desta Z, et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014;78(2):373-383.
53. Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51.
54. Tod M, Goutelle S, Bourguignon L, Bleyzac N. DDI-predictor. Available from: https://www.ddi-predictor.org/- opens in a new window. Accessed December 7, 2017.
55. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.
56. Kim A, Lim KS, Lee H, et al. A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. Int Clin Psychopharmacol. 2016;31(4):210-217.
57. Lozano R, Bibian C, Quilez RM, Gil J, Constante Y, Garcia-Arilla E. Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients. Br J Clin Pharmacol. 2014;77(6):1086-1087.
58. European Medicine Agency . Pharmacovigilance working party (PhVWP). Escitalopram - risk of QT interval prolongation. 2011. Available from: https://www.ema.europa.eu/docume...- opens in a new window. Accessed October 25, 2018.
59. Medicines and Healthcare products Regulatory Agency . Citalopram and escitalopram: QT interval prolongation. 2011. Available from: https://www.gov.uk/drug-safety-u...- opens in a new window. Accessed October 25, 2018.
60. US Food and Drug Administration . FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012. Available from: https://www.fda.gov/Drugs/DrugSa...- opens in a new window. Accessed October 25, 2018.
61. Cattaneo D, Baldelli S, Resnati C, et al. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: potential implications for clinical practice. World J Biol Psychiatry. 2018;n/a:1-7.
62. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;36(4):289-304.
63. Gutierrez M, Abramowitz W. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy. 2001;21(2):163-168.
64. I Lorenzini K, Calmy A, Ambrosioni J, et al. Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. AIDS. 2012;26(18):2417-2418.
65. O'Brien FE, O'Connor RM, Clarke G, Dinan TG, Griffin BT, Cryan JF. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology. 2013;38(11):2209-2219.
66. Wade AG, Crawford GM, Yellowlees A. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in major depressive disorder (MDD): an open-label, pilot study. BMC Psychiatry. 2011;11(1):42.
67. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688-700.
68. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy swedes. Br J Clin Pharmacol. 2003;56(4):415-421.
|
Language: | English.
|
Document Type: | ORIGINAL ARTICLES.
|
Journal Subset: | Pharmacology.
|
ISSN: | 0306-5251
|
NLM Journal Code: | au9, 7503323
|
DOI Number: | https://dx.doi.org/10.1111/bcp.1...- opens in a new window
|
Annotation(s) | |
|
|